PDCD1 and Merkel cell skin cancer: The efficacy and safety of avelumab (anti-PD-1) in MCC were assessed in a phase II clinical trial (JNCT02155647) including 88 immunocompetent patients with metastatic stage IV MCC, who were otherwise in a good general condition (Eastern Cooperative Oncology Group 0 or 1).